A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To assess the reliability of strength testing techniques among centers investigating patients with amyotrophic lateral sclerosis.
Methods: The authors compared test reliability in manual muscle testing (MMT) and maximal voluntary isometric contraction (MVIC) scores among institutions and test validity by comparing change over time between MMT and MVIC. The authors examined 63 subjects at 3-month intervals for 12 months. At enrollment and at 6 months, two physical therapists each examined the subjects twice. MMT scores were calculated as modifications of the Medical Research Council scale. MVIC scores were generated as standardized megascores. Intraclass correlation coefficients and coefficients of variation compared reproducibility, and Pearson correlation coefficients compared change over time. The power of each measure to detect disease progression over time was assessed by estimating coefficients of variation for the average change.
Results: Reproducibility between MVIC and MMT was equivalent. Sensitivity to detect progressive weakness and power to detect this change, however, favored MMT, an effect largely accounted for by the number of muscles sampled.
Conclusions: In multicentered trials, uniformly trained physical therapists reproducibly and accurately measure strength by both MMT and MVIC. The authors found MMT to be the preferred measure of global strength because of its better Pearson correlation coefficients, essentially equivalent reproducibility, and more favorable coefficient of variation.
- Received December 13, 2001.
- Accepted August 27, 2003.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
A Prospective, Quantitative Study of the Natural History of Facioscapulohumeral Muscular Dystrophy (FSHD)Implications for Therapeutic Trials et al.Neurology, January 01, 1997 -
Articles
Subcutaneous IGF-1 is not beneficial in 2-year ALS trialE. J. Sorenson, A. J. Windbank, J. N. Mandrekar et al.Neurology, November 24, 2008 -
Articles
Clinical evaluation of ALS drugsBenjamin Rix Brooks et al.Neurology, April 01, 1997 -
Articles
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisM.E. Cudkowicz, J.M. Shefner, D.A. Schoenfeld et al.Neurology, August 25, 2003